Triple-Negative Breast Cancer (TNBC) - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report 2023 To 2033

Triple-negative breast Cancer (TNBC) is a subtype of breast cancer characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) as determined by immunohistochemistry (IHC). TNBC is distinguished by its unique molecular profile, aggressive clinical behavior, distinct patterns of metastasis, and the absence of effective targeted therapies.

A significant proportion of BRCA1-associated hereditary and sporadic breast cancers are triple-negative, exhibiting a high expression of basal-like cytokeratins (CK5, CK14, CK17), P-cadherin, and HER1/EGFR. TNBC has a higher prevalence among pre-menopausal women of African-American descent, occurring up to three times more frequently compared to other populations.

Epidemiological studies have indicated that compared to luminal A tumors, basal-like tumors (a subset of TNBC) are more likely to occur in women with early menarche, higher parity, younger age at first full-term pregnancy, shorter duration of breastfeeding, higher body mass index, and a higher waist-to-hip ratio, particularly among pre-menopausal women.

Clinically, TNBC is known for its aggressive nature. It presents at a younger age, with a larger tumor size, higher grade, and a higher likelihood of node positivity. The recurrence of TNBC typically peaks early, between the first- and third-years post-diagnosis, with metastases frequently occurring in visceral organs, notably the lungs and brain, rather than the bones.

Although TNBC is generally associated with poor breast cancer-specific outcomes and a poor prognosis, many TNBC cases remain sensitive to chemotherapy. Nevertheless, the prognosis remains dire, with a high rate of relapse and mortality. Ongoing research focuses on developing therapies targeting specific biomarkers associated with TNBC or the basal-like subtype. Current investigational strategies include EGFR-targeted agents, androgen receptor-targeted agents, anti-angiogenic agents, and PARP inhibitors. However, these treatments are currently limited to clinical trials, and further research is required to identify therapeutic targets that provide significant clinical benefits.

The broad opportunity areas in Triple-negative breast Cancer (TNBC) include,

Closing statement: Targeting these opportunities would help drug marketers capture substantial patient share in Triple-negative breast Cancer (TNBC) and achieve commercial success.

Thelansis report on Triple-negative breast Cancer (TNBC) provides in-depth insights into the disease and patient segments, along with the areas of unmet need and drug development pipeline. The report answers key questions such as,

• What is the epidemiology for TNBC in the major markets, including the United States, Europe, Japan, China, and emerging markets?
• What are the estimated prevalence cases of TNBC in diagnosed and treated Populations?
• What are the drug treatment rates in TNBC?
• What are the KOL opinions on the unmet need areas for drug development in TNBC?
• What is the current and emerging competitive landscape in TNBC?
• What is the current market size in terms of TNBC sales?
• How will the landscape evolve over the next 10 years?

KOL Perspectives:

“This subtype of breast cancer is more prevalent among younger individuals, particularly African American women, Hispanic women, and women of Indian descent. Additionally, we observe a higher incidence of this subtype in women who carry a genetic mutation associated with breast cancer susceptibility, specifically the BRCA1 mutation."— USA – Based – Oncologist.

“In our evaluation of breast cancer tumors, we perform three essential tests: the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). If all three of these tests yield negative results, the cancer is categorized as triple-negative breast cancer.”— France – Based - Oncologist.

About Thelansis

Thelansis specializes in pharmaceutical and biopharmaceutical business research and consulting Company, published reports across the therapeutic area, including both rare / ultra-rare and mainstream indications. Over the period, we have built a strong repository of 6,000+ bio-pharma reports covering epidemiology studies and market forecasting, as well as opportunity assessment based on the KOL interviews and conference coverage. Competitive intelligence and conference coverage throughout the phases of asset development executed by a team with a mix of Scientific and Business backgrounds. As an organization, the major focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.

Offerings in the orphan indications: Syndicated reports/offerings for the major markets, epidemiology, customized market research including KOL interviews, PMR surveys, pipeline research, conference coverage, market forecast models, and consulting.

The developers and marketers of drugs in orphan indications can engage Thelansis for customized market research. They can gain possible solutions for ensuring considerable market penetration for their respective therapies.

?For more information, please contact:

Ankit Sahoo

Email- [email protected]

Contact No: +91- 6397-349664